Check for updates

OPEN ACCESS

EDITED BY Martin Wehling, University of Heidelberg, Germany

REVIEWED BY Sara Jarmakiewicz-Czaja, University of Rzeszów, Poland Chun-Hung Ko, Chi-Mei Medical Center, Taiwan Siti Chandra Widjanantie, University of Indonesia, Indonesia

*CORRESPONDENCE Jixiong Xu ⊠ jixiong.xu@ncu.edu.cn

RECEIVED 25 November 2024 ACCEPTED 23 January 2025 PUBLISHED 04 March 2025

CITATION

Liu Y, Guo Y, Xie S, Kong Y and Xu J (2025) Association between bone mineral density T-score and respiratory sarcopenia in older adults. *Front. Med.* 12:1534208.

doi: 10.3389/fmed.2025.1534208

COPYRIGHT

© 2025 Liu, Guo, Xie, Kong and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Association between bone mineral density T-score and respiratory sarcopenia in older adults

Ying Liu¹, Yutong Guo¹, Shun Xie², Yunyuan Kong³ and Jixiong Xu⁴*

¹Department of Emergency, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China, ²Department of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China, ³Department of Health Management, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China, ⁴Department of Endocrinology and Metabolism, The First Affiliated Hospital, Jiangxi Medical College. Nanchang University. Nanchang, China

Introduction: Respiratory sarcopenia, characterized by reduced respiratory muscle mass and strength, is underdiagnosed in older adults. This cross-sectional study aimed to investigate the association between bone mineral density (BMD) T-score and respiratory sarcopenia in a Chinese population.

Methods: A total of 530 participants aged \geq 60 years were recruited. Respiratory sarcopenia was diagnosed based on peak expiratory flow rate (PEFR) cutoffs. BMD was measured using dual-energy X-ray absorptiometry, and muscle mass was assessed using bioelectrical impedance analysis. Logistic regression models were used to analyze the association between BMD T-score and respiratory sarcopenia risk.

Results: Participants with respiratory sarcopenia exhibited lower BMD T-score, appendicular skeletal muscle index, trunk muscle mass ratio, and lung function parameters compared to those without respiratory sarcopenia. The odds ratio (95% Cl) for the lowest BMD T-score tertile with the risk of respiratory sarcopenia was 4.52 (1.71–13.1) compared with the highest tertile. This association remained significant after adjusting for confounding factors.

Conclusion: BMD T-score is significantly associated with an increased risk of respiratory sarcopenia in older adults. This finding highlights the importance of bone mass monitoring and early prevention strategies to reduce the incidence of respiratory sarcopenia.

KEYWORDS

association, bone mineral density, older adults, risk, respiratory sarcopenia

Introduction

Sarcopenia is an age-related accelerated muscle weakness and fiber atrophy in older individuals. The incidence of sarcopenia has gradually increased in recent years, it contributes to high morbidity and mortality in the elderly population (1, 2). Sarcopeniainduced difficulty in breathing and impaired cough reflex is a major risk factor for the recurrent development and progression of pneumonia (3, 4). The weakness in the mass and strength of the respiratory muscles should be given more attention. Among the expiratory muscles, the abdominal muscles hold a pivotal position. The four key abdominal muscles, the transverse abdominis, external oblique, internal oblique and rectus abdominis, contract to draw the abdominal wall inward, thereby increasing intra-abdominal pressure. This action pushes the diaphragm upward into the thoracic cavity. A clinical study demonstrated that an 8-week training program focused on abdominal muscles resulted in an increase in peak expiratory flow (PEFR) and maximal expiratory muscle pressure (5).

Kera et al. (6) introduced the term 'respiratory sarcopenia' for the first time and established a definition for it based on the PEFR. They used cut-off values of 4.40 L/s for men and 3.21 L/s for women to define respiratory sarcopenia (6). The definition was further refined by a collaborative effort of four professional organizations, which expanded the criteria to include not only muscle mass and function but also the impact on respiratory health and daily functioning (7). Weakness in the respiratory muscles can occur independently of systemic sarcopenia, affecting the function of these specific muscles without widespread muscle loss across the entire body. Subsequently, respiratory muscle dystrophy is closely associated with conditions such as chronic obstructive pulmonary disease (COPD), pneumonia, lung cancer, interstitial lung disease, and post-lung transplant complications (8). As respiratory sarcopenia a new conception, few relevant studies are available at present. It is underdiagnosed partially due to the insufficient awareness. Thus, it is necessary to study the epidemiology, risk factors and pathogenesis of respiratory sarcopenia.

Osteoporosis is a common condition among older adults and is characterized by low bone mineral density (BMD) and deterioration of bone microarchitecture leading to increased risk of fractures (9). BMD refers to the measurement of bone mineral content per unit area and serves as a clinical indicator of bone development and calcium content (10). A great number of studies indicated that low BMD is associated with increased incidence of stroke, coronary artery disease and cardiovascular disease-related mortality (11–13). Recently, it was revealed that sarcopenia was associated with fracture risk in older women (14). Thus, BMD is closely associated with the pathogenesis of sarcopenia. However, there have no studies assessing the association between BMD and respiratory sarcopenia.

To the best of our knowledge, no studies have specifically assessed the relationship between BMD and respiratory sarcopenia in older individuals. It is important to examine this relationship separately from the effects of BMD. This study aimed to investigate the association between BMD T-score and respiratory sarcopenia in older adults.

Methods

Study population

The study was approved by the ethics committee of the First Affiliated Hospital, Jiangxi Medical College, Nanchang University (IIT2023227). Written informed consent was obtained from all the participants. From June 2023 to August 2023, participants age greater than 60 years were collected from the physical examination records of elderly people in a community from Wuyuan, Jiangxi Province, China. All the collected data were stored in the Intelligent and Integrated Healthcare (IIH) system in the First Affiliated Hospital, Jiangxi Medical College, Nanchang University (Nanchang, China). The flow chart of this study was shown in Supplementary Figure S1. The inclusion criteria were: (a) Participants older \geq 60 years of age. (b) Enrolled subjects underwent the specified tests and examinations (questionnaire, blood tests, lung function, measure body composition, etc.). The exclusion criteria were: (a) Patients with significant liver and/or renal dysfunction, (b) Patients with systemic infections, (c) Thyroid dysfunction, (d) Patients with malignancies, (e) Patients with autoimmune disease, or glucocorticoid or immunosuppressant use, (f) congenital bone disease, (g) Airway obstructive diseases, including COPD, and asthma etc.

Diagnostic of respiratory sarcopenia using Kera et al. criterion

Respiratory sarcopenia was diagnosed using the criteria established by Kera et al. (6), which involves a PEFR cut-off of 4.40 L/s for men and 3.21 L/s for women to define the condition.

Diagnostic of respiratory sarcopenia using Sato et al. criterion

Respiratory sarcopenia was diagnosed using Sato et al. criteria (8), which involves a low PEFR and low appendicular skeletal muscle mass index (ASMI). Cutoff for low ASMI following the 2019 Asian Working Group for Sarcopenia (AWGS2) guidelines \leq 7.0 kg/m² for males and \leq 5.7 kg/m² for females (15).

Lung function

Lung function was assessed in each body position using Master Screen lung function instrument (Jaeger GmbH, Cologne, Germany). The spirometry system was calibrated prior to each assessment, based on the manufacturer's specifications. Room temperature was set optimally at 24–25°C. The researcher first demonstrated the protocol, and subjects then practiced two or three trials to ensure that they practiced correctly before true testing, based on the American Thoracic Society/European Respiratory Society recommendations. Subjects were asked to take deep maximal inhalation and then to exhale forcefully as much as they could and for as long as possible using a mouth piece. Lung function outcomes included FVC, FEV1, FEV1/FVC, and PEFR were measured by using FVC maneuver in the

Abbreviations: BMI, body mass index; WHR, waist-to-hip ratio; WC, waist circumference; ASMI, appendicular skeletal muscle index; VFA, visceral fat area; TMMR, trunk muscle mass ratio; FBG, fasting blood glucose; ALT, glutamic pyruvic transaminase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Cr, serum creatinine; ALT, alanine transaminase; BUN, serum blood urea nitrogen; ALB, albumin; PEFR, peak expiratory flow rate; FEV1, forced expiratory volume in first second; FVC, forced vital capacity; FEV1/FVC, forced expiratory volume in first second to forced vital capacity; HC, hip circumference.

spirometry test. The highest value from three tests that had a difference of less than 10% among them was used as the lung function score.

BMD T-score detection

BMD was assessed using the dual-energy X-ray bone mineral density device (PDXA LS-100). After performing air calibration and body membrane calibration, the BMD at the distal radius of the left forearm was recorded as the measurement value. All scans were conducted by a trained technician using standard positioning techniques and following the manufacturer's instructions. Using the World Health Organization's diagnostic criteria, BMD is generally expressed as a T-score, which is calculated as follows: T-score = (measured BMD – mean BMD of the average young population)/standard deviation of the BMD in the average young population.

Muscle mass

Body composition measurement was conducted by trained researchers using a professional bioelectrical impedance analysis device (InBody 770, BioSpace Co., Ltd., Seoul, Korea). The InBody 770 is a segmented impedance analysis device that employs eight tactile electrodes to measure voltage drops across the upper and lower extremities. It utilizes six frequency bands (1, 5, 50, 250, 500, and 1,000 kHz) to conduct 30 impedance measurements across five body segments: right upper limb, left upper limb, trunk, right lower limb, and left lower limb. Participants were instructed to wear lightweight clothing and stand barefoot on the metal footplates while holding the hand electrodes, ensuring that all metallic items were removed. The examination was conducted in a suitable environment, with the testing area specifically kept free of carpeting to avoid interference with the measurements. Participants were advised to fast and remain relaxed, with a strict caution to avoid any strenuous physical activity for at least 12 h before the assessment. To ensure the reliability and accuracy of the measurements, all researchers involved in the study underwent standardized training.

Anthropometric and laboratory data

All measurements will be performed in a standardized, comfortable, warm environment. All patients will be asked to overnight fast for at least 8 h prior to each examination. The measurements will be performed in the early morning before the patient's first meal. Serum biochemical parameters was measured using the Roche Cobas c702 analyzer (Roche Diagnostics, Indianapolis, IN, United States).

Waist circumference (WC), height and weight were collected, and the body mass index (BMI: body weight in kilograms divided by height in meters squared) was calculated. Central obesity was defined as a WC of \geq 90 cm for males and WC \geq 85 cm for females. Diabetes was defined based on self-report or a fasting blood glucose (FBG) level of \geq 7.0 mmol/L. FBG was determined using hexokinase method, while serum triglyceride (TG) levels were measured using enzyme colorimetry. In addition, biochemical parameters, including glutamic pyruvic transaminase (ALT), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), blood calcium, serum creatinine (Cr), blood urea nitrogen (BUN), and albumin (ALB), were measured professionally.

Statistical analysis

Non-normally distributed continuous variables were compared by Kruskal–Wallis test, whereas categorical variables were compared by χ^2 test or Fisher's exact test. The restricted cubic splines and logistic models were applied to evaluate the association between BMD T-score and respiratory sarcopenia in the cross-sectional study. In addition, the association between BMD T-score and the risk of respiratory sarcopenia was examined using multiple logistic regression analysis. Three separate models were constructed, each based on different correction factors. Statistical analyses were performed using the R statistical software (R version 4.2.1). A value of p < 0.05 was considered significant.

Results

Population characteristics

The cross-sectional population included 530 adult participants, among which 313 (59.06%) were males. The characteristics of participants in total or classified by respiratory sarcopenia are shown in Table 1. The median age of individuals with respiratory sarcopenia was 71 years (IQR, 66-76), which is older than the median age of participants without respiratory sarcopenia, who had a median age of 66 years (IQR, 62–70) (*p* < 0.001). Males accounted for 44.44% of the subjects with respiratory sarcopenia and 60.41% of the subjects without respiratory sarcopenia. In addition, the participants with respiratory sarcopenia had lower WHR, WC, ASMI, VFA, TMMR, FBG, ALB, calcium, TC, TG, LDL, HC, T-score, FVC, FEV1, and higher Cr levels compared with the population without respiratory sarcopenia. The prevalence of diabetes (10.25%) and obesity (19.18%) in the population without respiratory sarcopenia were higher than those in the respiratory sarcopenia population with the prevalence of 2.22%, and 13.33%, respectively (Table 1).

Associations between BMD T-score and respiratory sarcopenia risk

The associations between BMD T-score and respiratory sarcopenia risk were show in Table 2. Participants were categorized into tertiles based on their BMD T-scores. The odds ratios (OR) are presented with the highest BMD T-score tertile, which corresponds to the 'first T-score' in the table, as the reference group. Unadjusted models showed a higher risk of respiratory sarcopenia risk in the lowest BMD T-score tertile [OR 3.63, 95% CI 1.67–8.81] compared with the highest quartile. With the adjustment for age and gender, the association remained significant (OR 4.45, 95% CI 1.84–11.8). After further adjustment for age, gender, TC, TG, LDL, and HDL-C, the trend was almost the same as the crude model (OR 4.52, 95% CI 1.71–13.1). In addition, the restricted cubic splines were used to visualize the association of the TABLE 1 Baseline characteristics of 530 participants stratified by respiratory sarcopenia in the cross, sectional study.

Characteristic	Overall (<i>N</i> = 530)	Respiratory sarcopenia		<i>p</i> -value
		No (<i>N</i> = 485)	Yes (<i>N</i> = 45)	
Age, years	66.00 (62.00, 71.00)	66.00 (62.00, 70.00)	71.00 (66.00, 76.00)	< 0.001
Gender				0.037
Male	313 (59.06%)	293 (60.41%)	20 (44.44%)	
Female	217 (40.94%)	192 (39.59%)	25 (55.56%)	
BMI, Kg/m ²	22.90 (20.92, 25.20)	23.00 (21.00, 25.20)	21.50 (17.80, 24.60)	0.007
WHR	0.87 (0.84, 0.90)	0.87 (0.84, 0.90)	0.84 (0.81, 0.89)	0.002
WC, cm	78.80 (73.60, 85.18)	79.10 (74.20, 85.20)	73.00 (68.20, 85.00)	< 0.001
ASMI, Kg/m ²	6.41 ± 0.92	6.45 ± 0.88	6.02 ± 1.21	0.003
VFA	78.15 (56.85, 103.33)	79.70 (58.50, 104.10)	66.30 (43.30, 100.40)	0.019
TMMR	96.90 (93.10, 101.30)	97.10 (93.30, 101.30)	94.90 (90.40, 98.80)	0.022
FGB, mmol/L	5.50 (5.12, 5.98)	5.52 (5.13, 6.02)	5.32 (4.96, 5.64)	0.007
ALT, U/L	16.50 (12.90, 22.35)	16.60 (12.90, 22.70)	15.30 (11.80, 19.40)	0.143
AST, U/L	22.30 (19.10, 27.00)	22.20 (19.10, 26.90)	24.50 (20.20, 28.40)	0.144
BUN, mmol/L	4.85 (3.90, 5.80)	4.80 (3.90, 5.80)	5.00 (3.90, 6.20)	0.642
ALB, g/L	46.20 (44.70, 47.70)	46.30 (44.80, 47.80)	45.20 (43.50, 46.70)	0.004
Calcium, mmol/L	2.33 (2.27, 2.39)	2.33 (2.28, 2.39)	2.31 (2.26, 2.37)	0.07
Cr, µmol/L	71.00 (62.00, 84.00)	70.00 (62.00, 83.00)	85.00 (62.00, 90.00)	0.012
UA, mmol/L	318.50 (269.25, 378.75)	318.00 (269.00, 377.00)	327.00 (272.00, 400.00)	0.463
TC, mmol/L	4.91 (4.41, 5.48)	4.92 (4.47, 5.49)	4.70 (4.07, 5.16)	0.022
TG, mmol/L	1.47 (1.05, 2.03)	1.49 (1.06, 2.04)	1.19 (0.98, 1.69)	0.009
HDL-C, mmol/L	1.40 (1.17, 1.64)	1.40 (1.16, 1.64)	1.45 (1.30, 1.67)	0.118
LDL-C, mmol/L	2.81 (2.36, 3.36)	2.84 (2.38, 3.37)	2.59 (2.01, 3.13)	0.028
HC, cm	90.97 ± 5.34	91.22 ± 5.10	88.27 ± 6.98	< 0.001
T-score	-2.40 (-3.70, -1.20)	-2.40 (-3.60, -1.20)	-3.80 (-4.30, -2.20)	< 0.001
FVC, L	2.58 (2.12, 3.13)	2.63 (2.18, 3.16)	1.83 (1.51, 2.38)	< 0.001
FEV1, L	2.05 (1.71, 2.47)	2.09 (1.77, 2.49)	1.39 (1.23, 1.80)	< 0.001
FEV1/FVC (%)	79.12 (75.63, 83.11)	79.13 (75.71, 83.10)	78.57 (75.09, 83.11)	0.832
PEFR, L/s	5.25 (4.38, 6.47)	5.42 (4.54, 6.66)	3.16 (2.74, 3.90)	< 0.001
Diabetes				0.074
No	478 (90.19%)	434 (89.48%)	44 (97.78%)	
Yes	52 (9.81%)	51 (10.52%)	1 (2.22%)	
Central obesity				0.336
No	431 (81.32%)	392 (80.82%)	39 (86.67%)	
Yes	99 (18.68%)	93 (19.18%)	6 (13.33%)	

BMI, body mass index; WHR, waist-to-hip ratio; WC, waist circumference; ASMI, appendicular skeletal muscle index; VFA, visceral fat area; TMMR, trunk muscle mass ratio; FBG, fasting blood glucose; HDL-C, high, density lipoprotein cholesterol; LDL-C, low, density lipoprotein cholesterol; Cr, serum creatinine; UA, uric acid; ALT, alanine transaminase; BUN, serum blood urea nitrogen; ALB, albumin; PEFR, peak expiratory flow rate; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; FEV1/FVC, forced expiratory volume in first to forced vital capacity; HC, hip circumference.

BMD T-score and respiratory sarcopenia (Figure 1). The result showed that there is no non-linear relationship between BMD T-score and the risk of respiratory sarcopenia (p > 0.05).

detailed results of this analysis have been uploaded in Supplementary Tables S1, S2.

In addition, we also reanalyzed our data using the Sato et al. criterion. The flow chart of the diagnostic of respiratory sarcopenia by Sato et al. criterion was shown in Supplementary Figure S2. We found that the reanalysis has confirmed the consistency of our primary findings. The new criteria have not altered our main conclusions. The

Stratification analyses


Stratified analyses were performed by age (60–70, 70–80, and \geq 80 years), gender (male, female), central obesity (no, yes),

TABLE 2 Association among tertiles of BMD T-score and risk of respiratory sarcopenia.

T-score	Crude Model	Adjusted Model 1	Adjusted Model 2
	OR (95%CI)	OR (95%CI)	OR (95%CI)
First T-score	Reference	Reference	Reference
Second T-score vs. First T-score	1.30(0.50-3.49)	1.35(0.51-3.70)	1.41(0.52-3.95)
Third T-score vs. First T-score	3.63(1.67-8.81)	4.45(1.84-11.8)	4.52(1.71-13.1)
P for linear trend	-	_	0.5020

Model 1: adjusted for age (continuous), sex (male, or female).

Model 2: further adjusted (from Model 1) for BMI (continuous), central obese (yes, or no), diabetes (yes, or no), TC (continuous), TG (continuous), LDL (continuous), and HDL-C (continuous).



diabetes (no, yes) (Table 3). In the fully adjusted models of three different age groups, no statistically significant difference was observed between BMD T-score and risk of respiratory sarcopenia. For male individuals, there was a significant association between BMD T-score and risk of respiratory sarcopenia (OR: 2.28, 95% CI: 1.44–3.60, p < 0.001). For female individuals, there was a significant association between BMD T-score and risk of respiratory sarcopenia (OR: 1.63, 95% CI: 1.07-2.48, p = 0.022). For individuals without central obesity, there was a significant association between BMD T-score and risk of respiratory sarcopenia (OR: 1.72, 95% CI: 1.23-2.39, p = 0.001). For individuals without diabetes, there was a significant association between BMD T-score and risk of respiratory sarcopenia (OR: 1.72, 95% CI: 1.23–2.39, p = 0.001). However, for individuals without central obesity or diabetes, no statistically significant difference was observed between BMD T-score and risk of respiratory sarcopenia (Supplementary Figure S3).

Discussion

Osteoporosis and respiratory sarcopenia are common diseases in the elderly. There was no study have specifically assessed the relationship between BMD and respiratory sarcopenia in older individuals. This is the first cross-sectional study to provide evidence showing the association of BMD and respiratory sarcopenia in a large-sample Chinese population. The results indicated low BMD is significantly associated with a higher risk of respiratory sarcopenia independent of conventional confounding factors in the crosssectional population with 530 participants. This study suggests that BMD affects respiratory sarcopenia and might contribute to an increased risk of respiratory complications during aging. Thus, clinicians should be particularly wary of older adults with low BMD. Since the majority of older adults have declining bone mass due to natural aging, interventions to prevent further bone loss are needed in this population. Active intervention of patients with low BMD might decrease the risk of respiratory sarcopenia.

Age-related changes in function, structure, and biochemical make aging significantly impact an individual's quality of life. Osteoporosis and sarcopenia are two important musculoskeletal conditions adversely affecting the health of older individuals. The age-related decline in skeletal muscle function is defined as sarcopenia, which is characterized by muscle weakness and fiber atrophy. In the elderly, a decrease in skeletal muscle mass is often accompanied by a reduction in respiratory muscle mass. Respiratory sarcopenia causes deterioration of respiratory force generation and pulmonary function, which then adversely affect activities of daily living and quality of life (16, 17). Previous studies indicated that respiratory sarcopenia is a predictor of all-cause mortality in community-dwelling older adults (18). Thus, the concept of respiratory complications during aging. More attention should be paid to respiratory sarcopenia and related factors.

Low bone mass and osteoporosis are musculoskeletal disorders characterized by decreased bone density and abnormal changes in bone microstructure (19). Epidemiological studies indicate that the prevalence of low bone mass and osteoporosis is increasing with economic development, lifestyle conversing, and population aging worldwide. However, the relationship between BMD and respiratory sarcopenia remains unclear.

A meta-analysis has reported that osteoporosis and sarcopenia are closely associated with one another (20). It has been reported that bones and muscles intensely interact with each other (21). Osteoporosis and sarcopenia share common risk factors, such as aging, sex, physical inactivity, reduced specific nutrients (i.e., vitamin D), and specific hormones (i.e., growth factors and testosterone) (22, 23). The present study reached a unanimous conclusion in the crosssectional study that BMD is significantly associated with a higher risk of respiratory sarcopenia. The possible explanations may sarcopenia and respiratory sarcopenia share the same mechanisms.

The cause and mechanism underlying sarcopenia have remained unknown. Milewska et al. (24) reported that a higher prevalence of

Variables	Number	Percent	OR (95%CI)	<i>P</i> -value			
Age, years							
≥60, <70	365	68.9%	1.41(0.87-2.26)	0.160			
≥70, <80	148	27.9%	1.34(0.84-2.13)	0.219			
≥80	17	3.2%	1.45(0.50-4.21)	0.494			
Gender							
Male	313	59.1%	2.28(1.44-3.60)	<0.001			
Female	217	40.9%	1.63(1.07-2.48)	0.022			
Central obesity							
No	431	81.3%	1.72(1.23-2.39)	0.001			
Yes	99	18.7%	1.16(0.51-2.67)	0.719			
Diabetes							
No	478	90.2%	1.55(1.14-2.12)	0.006			
Yes	52	9.8%	5.86(0.73-46.86)	0.096			

TABLE 3 Stratified analyses of the associations (OR, 95% CIs) between BMD T-score and risk of respiratory sarcopenia.

sarcopenia risk in both women and men who had motor and respiratory system diseases, type 2 diabetes, or neurologic diseases. Gariballa and Alessa (25) reported that lycopene, retinol, red cell folate and zinc were significantly lower in sarcopenia patients. Yoo et al. (26) reported that alanine aminotransferase, alanine aminotransferase, and erythrocyte sedimentation rate are closely related to respiratory sarcopenia. Several mechanisms are potentially involved in pathogenesis of sarcopenia. Both intrinsic (e.g., inflammation, apoptosis, autophagy, mitochondria, neuromuscular junction, calcium metabolism) and extrinsic (e.g., endocrine, nutritional status, immobility) factors (27-32). However, the current understanding of how the skeleton affects muscles (especially for respiratory muscles) remain unclear. Recently, an increasing number of studies indicate that the skeleton secretes many endocrine factors that affect muscle homeostasis. Factors derived from bone tissues, including prostaglandin E2 (PGE2), sclerostin, FGF23, osteocalcin etc., play key roles in muscle homeostasis (33). Mo et al. (34) reported that PGE2 plays a crucial role in the proliferation and differentiation of myoblasts, making it potentially important for muscle myogenesis. Gu et al. (35) reported that mice injected with osteocalcin intraperitoneally could produce more IL-6 in their muscles, which induces autophagy in myocytes, potentially inhibiting muscular aging. Additionally, osteocalcin treatment could increase muscle mass and strength in aging mice (36). Thus, among individuals experiencing age-related bone loss, the secretion of bone-derived factors by the skeleton might be compromised, potentially triggering disruptions in respiratory related muscle homeostasis. However, the study on this topic is currently very restricted, it is crucial to investigate the association between BMD and respiratory sarcopenia. Endocrine and nutritional biomarkers could be included in future research to elucidate further the mechanisms linking BMD and respiratory sarcopenia.

In the present study, we also found participants with respiratory sarcopenia had lower WHR, WC, ASMI, VFA, TMMR, FBG, ALB, calcium, TC, TG, LDL, HC, T-score, FVC, FEV1, and higher Cr levels compared with the population without respiratory sarcopenia. We believe our results will enable new opportunities for providing novel considerations in the approach to respiratory sarcopenia.

The strengths of the present study were the inclusion of a large number of participants, adjustment to minimize residual confounders, handled target independent variables as both continuous variables and categorical variables to reduce the contingency in the data analysis, and the subgroup analyses. However, there are still some drawbacks and deficiencies. First, this study has an inherent bias due to its crosssectional design, and data validation cannot be finished as in prospective studies. Thus, a cause-and-effect relationship cannot be interpreted. Second, although we adjusted for a set of covariates, residual confounding is still possible. For example, the information on smoking status, drinking, and other elements is lacking in our study, these factors might also be potentially linked to BMD T-score and respiratory sarcopenia. Third, the population in our study was Chinese residents, and whether our findings could be generalized to other populations still needs further study. Finally, we did not have data on some important potential covariates that might either confound or modify the relationship between BMD and respiratory sarcopenia, such as diet, ambient temperature, and physical activity.

In conclusion, our study revealed an association between BMD T-score and respiratory sarcopenia in Chinese older adults. Additional studies are warranted to confirm our findings in prospective cohorts and to elucidate the potential mechanisms underlying the relationship between BMD T-score and respiratory sarcopenia.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the ethics committee of the First Affiliated Hospital, Jiangxi Medical College, Nanchang University. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of

written informed consent for participation from the participants or the participants' legal guardians/next of kin because in this study, the reason for waiving written informed consent was due to the study's minimal risk to participants. The research involved the analysis of existing data and measurements that were collected as part of routine clinical care, without any additional interventions or procedures that would require active consent from the participants. The study was designed to ensure that the participants' privacy and confidentiality were strictly maintained, with all data being anonymized and de-identified prior to analysis. Furthermore, the study was conducted in accordance with the ethical guidelines and regulations set forth by the Institutional Review Board (IRB), which approved the waiver of informed consent on the grounds that the research presented no more than minimal risk to the subjects and could not be carried out without the waiver. The waiver was also justified by the fact that the study's potential benefits to public health and the advancement of medical knowledge were deemed to outweigh the minimal risks involved.

Author contributions

YL: Writing – original draft, Writing – review & editing. YG: Writing – original draft. YK: Writing – original draft, Validation, Writing – review & editing. SX: Data curation, Writing – review & editing. JX: Funding acquisition, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was

References

1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. (2019) 48:16–31. doi: 10.1093/ageing/afy169

2. Woo J. Sarcopenia. Clin Geriatr Med. (2017) 33:305-14. doi: 10.1016/j. cger.2017.02.003

3. Komatsu R, Okazaki T, Ebihara S, Kobayashi M, Tsukita Y, Nihei M, et al. Aspiration pneumonia induces muscle atrophy in the respiratory, skeletal, and swallowing systems. *J Cachexia Sarcopenia Muscle*. (2018) 9:643–53. doi: 10.1002/jcsm.12297

4. Okazaki T, Ebihara S, Mori T, Izumi S, Ebihara T. Association between sarcopenia and pneumonia in older people. *Geriatr Gerontol Int.* (2020) 20:7–13. doi: 10.1111/ggi.13839

5. Rodríguez-Núñez I, Navarro X, Gatica D, Manterola C. Effect of abdominal muscle training on respiratory muscle strength and forced expiratory flows in sedentary, healthy adolescents. Arch Argent Pediatr. (2016) 114:434–40. doi: 10.5546/aap.2016.eng.434

6. Kera T, Kawai H, Hirano H, Kojima M, Watanabe Y, Motokawa K, et al. Definition of respiratory sarcopenia with peak expiratory flow rate. *J Am Med Dir Assoc.* (2019) 20:1021–5. doi: 10.1016/j.jamda.2018.12.013

7. Nagano A, Wakabayashi H, Maeda K, Kokura Y, Miyazaki S, Mori T, et al. Respiratory sarcopenia and Sarcopenic respiratory disability: concepts, diagnosis, and treatment. *J Nutr Health Aging*. (2021) 25:507–15. doi: 10.1007/s12603-021-1587-5

8. Sato S, Miyazaki S, Tamaki A, Yoshimura Y, Arai H, Fujiwara D, et al. Respiratory sarcopenia: a position paper by four professional organizations. *Geriatr Gerontol Int.* (2023) 23:5–15. doi: 10.1111/ggi.14519

9. Nagendra L, Chandran M, Reginster JY, Bhadada SK, Bhattacharya S, Dutta D, et al. Cost-effectiveness of FRAX[®]-based intervention thresholds for management of osteoporosis in Indian women: a Markov microsimulation model analysis. *Osteoporos Int.* (2024). doi: 10.1007/s00198-024-07328-6

10. Bihun H, Abdullah N, Abdul Murad NA, Chin SF, Arifin ASK, Khuzaimi AN, et al. Body fat distribution and bone mineral density in a multi-ethnic sample of supported by the Natural Science Foundation of Jiangxi Province (no. 20232ABC03W01).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative Al statement

The authors declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2025.1534208/ full#supplementary-material

postmenopausal women in the Malaysian cohort. Arch Osteoporos. (2024) 19:73. doi: 10.1007/s11657-024-01435-x

11. Tsai YL, Chuang YC, Cheng YY, Deng YL, Lin SY, Hsu CS. Low bone mineral density as a predictor of mortality and infections in stroke patients: a hospital-based study. *J Clin Endocrinol Metab.* (2024) 109:3055–64. doi: 10.1210/clinem/dgae365

12. Smith C, Sim M, Ilyas Z, Gilani SZ, Suter D, Reid S, et al. Automated abdominal aortic calcification and major adverse cardiovascular events in people undergoing osteoporosis screening: the Manitoba bone mineral density registry. *J Bone Miner Res.* (2025). doi: 10.1093/jbmr/zjae208

13. Li H, Wang B, Xu D, Zhang J, Wang C. Bone mineral density is negatively associated with risk of all-cause and cardiovascular mortality among adults with type 2 diabetes mellitus: a cross-sectional study of the NHANES 2005-2010, 2013-2014. *Rev Cardiovasc Med.* (2024) 25:434. doi: 10.31083/j.rcm2512434

14. Gandham A, Gregori G, Johansson L, Johansson H, Harvey NC, Vandenput L, et al. Sarcopenia definitions and their association with fracture risk in older Swedish women. *J Bone Miner Res.* (2024) 39:453–61. doi: 10.1093/jbmr/zjae026

15. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. *J Am Med Dir Assoc.* (2020) 21:300-7.e2. doi: 10.1016/j.jamda.2019.12.012

16. Andrade FP, Borges S, da Silva Filho CA, Martins TF, Benvenutti H, de Freitas JMC, et al. Respiratory sarcopenia screening in dialysis patients: cross-sectional and multicentre study protocol. *BMC Nephrol.* (2024) 25:41. doi: 10.1186/s12882-023-03390-0

17. Choi JY, Rhee CK, Kim SH, Jo YS. Muscle mass index decline as a predictor of lung function reduction in the general population. *J Cachexia Sarcopenia Muscle.* (2025) 16:e13663. doi: 10.1002/jcsm.13663

18. Kera T, Kawai H, Ejiri M, Ito K, Hirano H, Fujiwara Y, et al. Respiratory sarcopenia is a predictor of all-cause mortality in community-dwelling older adultsthe Otassha study. *J Cachexia Sarcopenia Muscle*. (2023) 14:1894–9. doi: 10.1002/ jcsm.13266 19. Zhou F, Wang Z, Li H, Wang D, Wu Z, Bai F, et al. USP7 inhibition promotes early Osseointegration in senile osteoporotic mice. *J Dent Res.* (2025) 104:86–96. doi: 10.1177/00220345241288570

20. Okamura H, Ishikawa K, Kudo Y, Matsuoka A, Maruyama H, Emori H, et al. Risk factors predicting osteosarcopenia in postmenopausal women with osteoporosis: a retrospective study. *PLoS One.* (2020) 15:e0237454. doi: 10.1371/journal.pone.0237454

21. Hatakeyama J, Inoue S, Jiang H, Yokoi R, Moriyama H. Exercise-induced interactions between skeletal muscle and bone via myokines and osteokine in mice: role of FNDC5/irisin, IGF-1, and osteocalcin. *Bone*. (2025) 190:117314. doi: 10.1016/j.bone.2024.117314

22. Stromsnes K, Fajardo CM, Soto-Rodriguez S, Kajander ERU, Lupu RI, Pozo-Rodriguez M, et al. Osteoporosis: causes, mechanisms, treatment and prevention: role of dietary compounds. *Pharmaceuticals*. (2024) 17:17. doi: 10.3390/ph17121697

23. Toba A, Ishikawa J. Sarcopenia as a risk factor for hypertension. *Hypertens Res.* (2024) 47:3363-6. doi: 10.1038/s41440-024-01898-y

24. Milewska M, Przekop Z, Szostak-Węgierek D, Chrzanowska M, Raciborski F, Traczyk I, et al. Prevalence of risk of sarcopenia in polish elderly population-a population study. *Nutrients.* (2022) 14:14. doi: 10.3390/nu14173466

25. Gariballa S, Alessa A. Association between nutritional blood-based biomarkers and clinical outcome in sarcopenia patients. *Clin Nutr ESPEN*. (2018) 25:145–8. doi: 10.1016/j.clnesp.2018.03.002

26. Yoo JI, Ha YC, Choi H, Kim KH, Lee YK, Koo KH, et al. Malnutrition and chronic inflammation as risk factors for sarcopenia in elderly patients with hip fracture. *Asia Pac J Clin Nutr.* (2018) 27:527–32. doi: 10.6133/apjcn.082017.02

27. Brzeszczyński F, Hamilton D, Bończak O, Brzeszczyńska J. Systematic review of sarcopenia biomarkers in hip fracture patients as a potential tool in clinical evaluation. *Int J Mol Sci.* (2024) 25:25. doi: 10.3390/ijms252413433

28. Wang T, Zhou D, Hong Z. Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions. *MedComm.* (2020) 6:e70030. doi: 10.1002/mco2.70030

29. Xu H, Brown JL, Bhaskaran S, Van Remmen H. Reactive oxygen species in the pathogenesis of sarcopenia. *Free Radic Biol Med.* (2024) 227:446–58. doi: 10.1016/j. freeradbiomed.2024.11.046

30. Millan-Domingo F, Garcia-Dominguez E, Gambini J, Olaso-Gonzalez G, Viña J, Gomez-Cabrera MC. Diet and exercise in frailty and sarcopenia. *Mol Aspects Med.* (2024) 100:101322. doi: 10.1016/j.mam.2024.101322

31. Zheng G, Cao J, Wang XH, He W, Wang B. The gut microbiome, chronic kidney disease, and sarcopenia. *Cell Commun Signal.* (2024) 22:558. doi: 10.1186/s12964-024-01922-1

32. Damanti S, Senini E, De Lorenzo R, Merolla A, Santoro S, Festorazzi C, et al. Acute sarcopenia: mechanisms and management. *Nutrients*. (2024) 16:3428. doi: 10.3390/ nu16203428

33. Dong Y, Yuan H, Ma G, Cao H. Bone-muscle crosstalk under physiological and pathological conditions. *Cell Mol Life Sci.* (2024) 81:310. doi: 10.1007/s00018-024-05331-y

34. Mo C, Zhao R, Vallejo J, Igwe O, Bonewald L, Wetmore L, et al. Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation. *Cell Cycle*. (2015) 14:1507–16. doi: 10.1080/15384101.2015.1026520

35. Gu P, Tao D, Xu Y, Yang Q, Bai T, Hu S, et al. Osteocalcin inhibits myocyte aging through promotion of starvation-induced autophagy via IL-6/STAT3 signaling. *Exp Gerontol.* (2023) 173:112082. doi: 10.1016/j.exger.2023.112082

36. Wang H, Li J, Xu Z, Wu F, Zhang H, Yang C, et al. Undercarboxylated osteocalcin inhibits the early differentiation of osteoclast mediated by Gprc6a. *PeerJ.* (2021) 9:e10898. doi: 10.7717/peerj.10898